NCT03150966View on ClinicalTrials.gov

The Immunomodulatory Effects of Oral Nanocurcumin in Multiple Sclerosis Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

June 8, 2016

Primary Completion Date

August 10, 2017

Study Completion Date

November 7, 2017

Conditions
Multiple Sclerosis
Interventions
DRUG

Nanocurcumin

Patients will take 80 mg nanocurcumin in the form of capsules daily during the 6 month study period

DRUG

Placebo

Patients will take placebo in the form of capsules daily during 6 months study period

Trial Locations (1)

Unknown

Drug Applied Research Center, Tabriz, Iran, Tabriz

All Listed Sponsors
lead

Tabriz University of Medical Sciences

OTHER

NCT03150966 - The Immunomodulatory Effects of Oral Nanocurcumin in Multiple Sclerosis Patients | Biotech Hunter | Biotech Hunter